Comparative Pharmacology
Head-to-head clinical analysis: NEPHRAMINE 5 4 versus TRAVASOL 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHRAMINE 5 4 versus TRAVASOL 8 5 W ELECTROLYTES.
NEPHRAMINE 5.4% vs TRAVASOL 8.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Travasol 8.5% with Electrolytes is a parenteral nutrition solution providing amino acids for protein synthesis, electrolytes for maintenance of acid-base balance and osmotic pressure, and calories to prevent protein catabolism and promote anabolism.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
Intravenous infusion via central vein: 500 mL to 2000 mL per day, infused at a rate not exceeding 0.2 g/kg/hour of amino acids. Dosing individualized based on caloric and protein requirements.
None Documented
None Documented
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Variable; amino acids have rapid distribution (minutes) and metabolic elimination (half-life ~1-2 hours for most). Clinical context: continuous infusion maintains steady state; half-life not typically used for dosing but reflects rapid clearance.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Components are eliminated via metabolic pathways (e.g., amino acids undergo deamination, protein synthesis) and renal excretion of waste products (urea, creatinine). 100% of nitrogenous waste is renally excreted; electrolytes are excreted renally proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution